Form DEFA14A Prime Medicine, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall St futures edge up as Hormuz progress weighs down oil prices
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Prime Medicine (PRME) PT Lowered to $12 at Chardan Capital Markets
May 19, 2025 1:12 PM EDTChardan Capital Markets analyst Geulah Livshits lowered the price target on Prime Medicine (NASDAQ: PRME) to $12.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "On 19 May, Prime Medicine reported its CGD prime editing asset PM359 had shown impressive activity in the... More
Prime Medicine (PRME) PT Lowered to $9 at Jefferies
May 19, 2025 10:37 AM EDTJefferies analyst Maury Raycroft lowered the price target on Prime Medicine (NASDAQ: PRME) to $9.00 (from $13.00) while maintaining a Buy rating.
The analyst comments "PRME showed solid proof-of-concept DHR restoration in 1 adult pt w/ p47 CGD that derisks prime editing platform, which mgmt believes is... More
Citi on Prime Medicine (PRME) with shares down 20pct: 'Initial Human Data from a Prime Editing Therapy Show Promise, but Financing Risk Remains a Key Overhang'
May 19, 2025 10:28 AM EDTCiti analyst Samantha Semenkow reiterated a Buy rating and $10.00 price target on Prime Medicine (NASDAQ: PRME).
The analyst comments "Prime announced CFO Allan Reine will succeed Keith Gottesdiener as CEO and that Jeff Marrazzo (founder of Spark Therapeutics) will... More
